Industry

Based on DESTINY-Gastric02, which showed Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated clinically meaningful efficacy and DESTINY-Gastric01, which showed improved overall survival compared to chemotherapy TOKYO & MUNICH–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of … [Read more…]

Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in a Phase I/IIa trial STRASBOURG, France–(BUSINESS WIRE)–$TNG–Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and … [Read more…]

WROCLAW, Poland–(BUSINESS WIRE)–Jabil Inc. (NYSE: JBL) has officially opened a new design center in Wroclaw, Poland, that will develop leading-edge technologies for multiple industries including the automotive and healthcare sectors. The opening of the 10,000 square foot center will provide a number of highly skilled engineering jobs and extends Jabil’s design capabilities in concept feasibility, … [Read more…]

– Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer’s – – The level of beta-amyloid removal by gantenerumab was lower than expected – – Topline data will be presented at the Clinical Trials on Alzheimer’s Disease Conference – – Genentech is committed to the … [Read more…]

Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab Phase 2 data to be presented at ASH 2022 Annual Congress Innovative ANKET™ pipeline will be on display at ASH 2022 Annual Congress Cash position of €151.4 million1 as of … [Read more…]

GALWAY, Ireland–(BUSINESS WIRE)–Late in 2021, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia Air™ utilizing Aerogen’s proprietary aerosol drug delivery technology. In 2022 Convidecia Air™ was granted Emergency Use Authorization as a booster dose … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2022 third quarter results and latest corporate development. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare said, “We successfully got listed on the STAR Board of the Shanghai Stock Exchange, which makes InnoCare become the … [Read more…]

PORTLAND, Ore.–(BUSINESS WIRE)–Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting. The presentation titled, “Toward Safer Glucocorticoid Therapy” examined the ability … [Read more…]

CHICAGO–(BUSINESS WIRE)–Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) announced today that management will participate in investor meetings at Nareit’s REITworld 2022 Annual Conference (the “Nareit Conference”) on November 15-16, 2022. Any Company written materials accompanying the participation at the Nareit Conference will be available on the Company’s website on or about November 14, 2022. … [Read more…]

LEHI, Utah–(BUSINESS WIRE)–Owlet, Inc. (NYSE: OWLT) will release its third quarter 2022 financial results after the market closes on November 14, 2022. Owlet will issue a copy of the earnings release via Business Wire and include a copy on Owlet’s Investor Relations website at investors.owletcare.com. Owlet’s President and Chief Executive Officer, Kurt Workman, and Chief … [Read more…]